Courage Therapeutics Secures $11M Seed Round Led by Arsenal Bridge Ventures

Why It Matters

The infusion of seed capital enables Courage Therapeutics to accelerate R&D on high‑need obesity and wasting disease treatments, a market projected to grow sharply as prevalence rises. Investor backing signals confidence in the company’s approach and may attract further funding for later‑stage trials.

Deal Summary

Courage Therapeutics announced the closing of a seed financing round exceeding $11 million, led by venture firm Arsenal Bridge Ventures and supported by existing backers. The funding will accelerate development of novel treatments for genetic and dietary obesity and wasting diseases.